We're excited to have you on board

	This Stock Priced Under $10 Is Poised To Break Out Zacks Member, I posted a new buy recommendation to our Stocks Under $10 portfolio today and you can be among the first to see it. It's a Zacks Rank #1 (Strong Buy) with an A for Growth. This medical testing company offers cutting-edge technologies that cater to diverse sectors, from healthcare institutions and clinical laboratories to government agencies and commercial entities, making it a pivotal player in the dynamic landscape of medical diagnostics and public health. Please don't wait to look into it because I don't expect it to be priced under $10 for long. Like all the recommendations in our Stocks Under $10 portfolio it offers: 1. Profitable long-term gain potential. We've recently closed positions with gains of +79.2%, +100.6% and even +221.2%.¹ 2. Excellent prospects for early price movement. Proprietary Zacks signals indicate that significant growth could start now. See it now for only $1. This may be your last chance to pick up shares while they're still less than $10. Plus that same dollar also gives you 30-day access to all Zacks private trading and investing services. No reason to hesitate. There's not a cent of further obligation. Bonus Report: You can also download Zacks' just-released Special Report, 7 Best Stocks for the Next 30 Days. From our proven list of 220 Zacks Rank #1 Strong Buys, our team of experts handpicked these 7 for immediate breakout. Don't miss this opportunity. Click the button below to take advantage. ▶ See Stocks Now All the Best, Brian Bolan Editor of Stocks Under $10
	¹ The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research's newsletter editors and may represent the partial close of a position. This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms of Service". https://www.zacks.com/terms_of_service Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or US investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through December 4, 2023. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank #1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance_disclosure for information about the performance numbers displayed above. Zacks Emails If you would prefer to not receive future profit-producing emails from Zacks.com the primary purpose of which is the commercial advertisement or promotion of a commercial product or service, then please click here and confirm your request. If you have trouble with the unsubscribe link, please email support@zacks.com. Zacks Investment Research 10 S. Riverside Plaza, Suite 1600 Chicago, IL 60606